Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 11/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285972 | 0.91 | PTPN1 (0.56) | PTGER1PTPN1KDM4EALDH1A1PKM | |
| SCHEMBL6279323 | 0.91 | PTPN1 (0.56) | PTGER1PTPN1KDM4EALDH1A1PKM | |
| SCHEMBL6279663 | 0.91 | PTPN1 (0.56) | PTGER1PTPN1KDM4EALDH1A1PKM | |
| SCHEMBL6282177 | 0.91 | PTPN1 (0.56) | PTGER1PTPN1KDM4EALDH1A1PKM | |
| SCHEMBL6285365 | 0.86 | NR5A1 (0.49) | PTGER1PTPN1KDM4EALDH1A1PKM | |
| SCHEMBL6287192 | 0.83 | PTPN1 (0.67) | PTGER1PTPN1PKMLTA4H | |
| SCHEMBL6282831 | 0.83 | PTPN1 (0.67) | PTGER1PTPN1PKMLTA4H | |
| SCHEMBL6285787 | 0.83 | PTPN1 (0.67) | PTGER1PTPN1PKMLTA4H | |
| SCHEMBL6287247 | 0.83 | PTPN1 (0.67) | PTGER1PTPN1PKMLTA4H | |
| SCHEMBL6285933 | 0.83 | PTPN1 (0.56) | PTGER1PTPN1KDM4EALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | PTGER1 3484/4885PTPN1 2/4885CYP2C9 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.